Blood Coagulation & Fibrinolysis : an International Journal in Haemostasis and Thrombosis
-
Publication Venue For
- Race and sex differences in thrombogenicity: risk of ischemic events following coronary stenting.. 19:268-275. 2008
- Effects of recombinant activated factor VII on thrombin-mediated feedback activation of coagulation.. 19:135-141. 2008
- Warfarin reversal with prothrombin complex concentrate confers better antifibrinolytic activity compared with recombinant activated factor VII.. 19:106-108. 2008
- ABO blood group and bleeding after coronary artery bypass graft surgery.. 18:781-785. 2007
- Inflammatory changes during the 'common cold' are associated with platelet activation and increased reactivity of platelets to agonists.. 18:713-718. 2007
- Thrombin-activated thrombelastography for evaluation of thrombin interaction with thrombin inhibitors.. 18:761-767. 2007
- Does heart failure etiology, New York Heart Association class, or ejection fraction affect the ability of clopidogrel to inhibit heightened platelet activity?. 18:91-96. 2007
- Effects of pre-analytical variables on the anti-activated factor X chromogenic assay when monitoring unfractionated heparin and low molecular weight heparin anticoagulation.. 16:173-176. 2005
- The platelet-related effects of tenecteplase versus alteplase versus reteplase.. 16:1-7. 2005
- Enhanced platelet/endothelial activation in depressed patients with acute coronary syndromes: evidence from recent clinical trials.. 14:563-567. 2003
- Management of lepirudin therapy for a patient with antiphospholipid antibody syndrome using the whole blood ecarin clot time and activated partial thromboplastin time.. 14:601-604. 2003
- Binding of factor VIII inhibitors to discrete regions of the factor VIII C2 domain disrupt phospholipid binding.. 14:361-368. 2003
- Analyzing fibrin clot structure using a microplate reader.. 13:533-539. 2002
- Abnormal optical waveform profiles in coagulation assays from patients with antiphospholipid antibodies.. 13:7-17. 2002
- Hemostatic effects of antithrombin III supplementation during cardiac surgery: results of a prospective randomized investigation.. 12:25-31. 2001
- The effect of factor X level on thrombin generation and the procoagulant effect of activated factor VII in a cell-based model of coagulation.. 11 Suppl 1:S3-S7. 2000
- Tissue factor de-encryption: ionophore treatment induces changes in tissue factor activity by phosphatidylserine-dependent and -independent mechanisms.. 10:201-210. 1999
- A possible mechanism of action of activated factor VII independent of tissue factor.. 9 Suppl 1:S15-S20. 1998
- Activated factor VII activates factors IX and X on the surface of activated platelets: thoughts on the mechanism of action of high-dose activated factor VII.. 9 Suppl 1:S61-S65. 1998
- The effects of activated factor VII in a cell-based model for tissue factor-initiated coagulation.. 9 Suppl 1:S21-S25. 1998
- Plasma levels of factors II, VII and X and their relationship to the international normalized ratio during chronic warfarin therapy.. 8:48-53. 1997
- Serial changes of natural antithrombotics during myocardial ischemia-reperfusion in swine. Effects of magnesium, diltiazem, and a novel Mac-1 inhibitor.. 7:632-640. 1996
- Transmission of a procoagulant signal from tissue factor-bearing cell to platelets.. 7:459-464. 1996
- Evaluation of a modified procedure for Staclot LA for the confirmation of lupus anticoagulants.. 5:601-604. 1994
- Platelets contain releasable coagulation factor IX antigen: response.. 5:657-658. 1994
- Platelets contain releasable coagulation factor IX antigen.. 4:905-910. 1993
- Lipoprotein(a) inhibits plasminogen activation in a template-dependent manner.. 2:759-764. 1991
- Tissue plasminogen activator and thrombin generation measurements using the Thrombinoscope.. 17:603-604. 2006